Nuo Therapeutics, Inc. (AURX)
OTCMKTS
· Delayed Price · Currency is USD
1.144
-0.156 (-12.02%)
Apr 28, 2026, 10:30 AM EST
Nuo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3.31 | 1.37 | 0.61 | 0.11 | - | Upgrade
|
| Revenue Growth (YoY) | 142.72% | 124.34% | 442.12% | - | - | Upgrade
|
| Cost of Revenue | 1.1 | 0.3 | 0.13 | 0.02 | - | Upgrade
|
| Gross Profit | 2.22 | 1.06 | 0.48 | 0.09 | - | Upgrade
|
| Selling, General & Admin | 4.73 | 3.52 | 3.65 | 3.41 | 0.09 | Upgrade
|
| Operating Expenses | 4.73 | 3.52 | 3.65 | 3.41 | 0.09 | Upgrade
|
| Operating Income | -2.52 | -2.46 | -3.17 | -3.32 | -0.09 | Upgrade
|
| Interest Expense | -0 | - | -0 | -0 | - | Upgrade
|
| Interest & Investment Income | - | 0 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0 | - | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -2.51 | -2.46 | -3.17 | -3.32 | -0.09 | Upgrade
|
| Other Unusual Items | - | 0.13 | - | 0.15 | - | Upgrade
|
| Pretax Income | -2.51 | -2.32 | -3.17 | -3.17 | -0.09 | Upgrade
|
| Net Income | -2.51 | -2.32 | -3.17 | -3.17 | -0.09 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.8 | Upgrade
|
| Net Income to Common | -2.51 | -2.32 | -3.17 | -3.17 | -0.89 | Upgrade
|
| Shares Outstanding (Basic) | 47 | 45 | 42 | 40 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 45 | 42 | 40 | 30 | Upgrade
|
| Shares Change (YoY) | 4.16% | 7.95% | 5.19% | 32.03% | 10.93% | Upgrade
|
| EPS (Basic) | -0.05 | -0.05 | -0.08 | -0.08 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.05 | -0.08 | -0.08 | -0.03 | Upgrade
|
| Free Cash Flow | -1.14 | -2.39 | -3.18 | -3.77 | -0.12 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.05 | -0.07 | -0.09 | -0.00 | Upgrade
|
| Gross Margin | 66.94% | 77.82% | 79.28% | 82.88% | - | Upgrade
|
| Operating Margin | -75.95% | -180.04% | -520.65% | -2958.21% | - | Upgrade
|
| Profit Margin | -75.82% | -170.21% | -521.17% | -2825.60% | - | Upgrade
|
| Free Cash Flow Margin | -34.40% | -174.82% | -521.76% | -3355.12% | - | Upgrade
|
| EBITDA | -2.43 | -2.43 | -3.15 | -3.31 | - | Upgrade
|
| EBITDA Margin | -73.37% | -178.35% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.09 | 0.02 | 0.02 | 0.01 | - | Upgrade
|
| EBIT | -2.52 | -2.46 | -3.17 | -3.32 | -0.09 | Upgrade
|
| EBIT Margin | -75.95% | -180.04% | - | - | - | Upgrade
|
| Revenue as Reported | 3.31 | 1.37 | 0.61 | 0.11 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.